about
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathwayIntegrative clinical genomics of advanced prostate cancer.DNA-Repair Defects and Olaparib in Metastatic Prostate CancerMulti-purpose utility of circulating plasma DNA testing in patients with advanced cancersUnbiased and automated identification of a circulating tumour cell definition that associates with overall survivalFailure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors.Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer.Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trailUpdate on tubulin-binding agents.The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer.Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.Tumor clone dynamics in lethal prostate cancerCirculating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancerCirculating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug AdministrationThe association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patientsProstate epithelial stem cells.Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.CYP17 inhibition as a hormonal strategy for prostate cancer.First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangementUtilizing circulating tumor cells: challenges and pitfalls.Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients.Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer.Prostate cancer in 2011: redefining the therapeutic landscape for CRPC.Novel strategies to test biological hypotheses in early drug development for advanced prostate cancer.Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone.Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospectsEvolution of androgen receptor targeted therapy for advanced prostate cancer.Targeting extra-gonadal androgens in castration-resistant prostate cancer.
P50
Q24603649-BC557D58-330B-4091-9D65-6D5A30ED7AF4Q27853170-7D970BF2-8566-41B0-829F-121491CB4D0FQ27853235-7D4E0A5B-9AC5-47D4-9318-9ED82053983DQ28484970-6093D602-A0B1-4ACE-A05B-97E09FD48130Q28743067-A5370DB9-A77A-4AF6-9EC3-98C6AAD090ABQ31028126-C091939B-C73A-46AC-BCC6-0FF099FB75DFQ33385572-DA804EDD-AE55-4661-9FA5-164C278739E6Q34002037-0778D610-16AF-4B35-BA29-CB8E5162F674Q34098110-057CC3B1-2777-45FA-A076-E1F3E0742C30Q34113504-FF1CFD23-A332-4E29-BD0F-AE9BF73C7FF8Q34503114-15195DAE-8517-4219-BDAD-8B1A55DEF935Q34629038-226043F4-59EE-46B3-8873-B50E9B5564EBQ34796583-CB18E4D0-F870-4196-BF02-E804BF246FF4Q34798892-3479272B-D60A-40B9-B26B-F9ACC520C977Q34973214-8042B965-2035-423E-A97C-AAA7466F8D60Q34985794-A39FEA01-289C-454B-8A02-BE3BC0272464Q35540013-F5E7EC9B-D838-4492-97B5-DD61C5290D9AQ35575930-446959BF-5620-40D4-BAA5-E7CB0D1F6514Q35584698-AC6B1817-109D-4D19-9074-1D7D0410A3CDQ35603660-B6247F4D-6A7E-46C6-9F4A-A1AA9C438C74Q35879087-28425FB5-52F9-4ACF-A4AC-F607ED456FD2Q36087929-482A26FA-55D3-41BD-A467-F54110CBD3E1Q36242802-FDC8240B-61C1-407B-9868-FE010C362EA0Q36287422-FFE88F70-2BDE-47DD-A2B6-29586EBEDDB6Q36318592-0469467B-06A6-43FE-8951-176677259F48Q36597347-E0B6D5BC-B3E1-4476-A8CA-C02BC74F65C5Q36707077-78721F48-1DC6-45A7-882C-DAFFD70BDD4CQ36930831-E0A7D7DF-86E1-4D2C-91DE-B385320B2616Q37317810-E9AD382B-4815-47ED-B26F-33870478A33FQ37323018-C94D9083-D4D5-4FFA-BF17-F4F512AD85C1Q37400523-AD2E2CE3-84E0-4628-96E5-17033267F363Q37812976-76010E92-0B7B-464F-98EA-4C3AFF502903Q37890713-4E6E9B71-32BD-4890-85BF-EB1E2B560236Q37944070-C54DC24D-C928-45C7-A63D-C80AA97A88D9Q37976255-6C92DBDC-65A3-4164-B001-A595D0D7EFC2Q38064394-DDF71F95-5F56-407A-A6F8-7B3296A70C73Q38098658-C9AE5C6F-3E83-4439-B161-899E5A0913BAQ38212470-7255F6C1-7C68-422E-BEFD-AB89875CF9E0Q38212716-469E99CD-0646-44F3-A42D-5ED29AA229E9Q38253870-48D70F74-D4BC-4F10-9864-23ADC50CB47C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gerhardt Attard
@ast
Gerhardt Attard
@en
Gerhardt Attard
@es
Gerhardt Attard
@nl
Gerhardt Attard
@sl
type
label
Gerhardt Attard
@ast
Gerhardt Attard
@en
Gerhardt Attard
@es
Gerhardt Attard
@nl
Gerhardt Attard
@sl
prefLabel
Gerhardt Attard
@ast
Gerhardt Attard
@en
Gerhardt Attard
@es
Gerhardt Attard
@nl
Gerhardt Attard
@sl
P106
P21
P31
P496
0000-0002-4811-7983